Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV.
Ebola virus glycoprotein
HIV-1 Envelope glycoprotein
human immunodeficiency virus type 1 (HIV-1)
vesicular stomatitis virus (VSV) vector
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
12 May 2023
12 May 2023
Historique:
received:
08
04
2023
revised:
02
05
2023
accepted:
04
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) and cytoplasmic tail (CT) of SIVMac239 results in high expression on the approved Ebola vaccine, rVSV-ZEBOV, also harboring the Ebola Virus (EBOV) glycoprotein (GP). Codon-optimized (CO) Env chimeras derived from a subtype A primary isolate (A74) are capable of entering a CD4+/CCR5+ cell line, inhibited by HIV-1 neutralizing antibodies PGT121, VRC01, and the drug, Maraviroc. The immunization of mice with the rVSV-ZEBOV carrying the CO A74 Env chimeras results in anti-Env antibody levels as well as neutralizing antibodies 200-fold higher than with the NL4-3 Env-based construct. The novel, functional, and immunogenic chimeras of CO A74 Env with the SIV_Env-TMCT within the rVSV-ZEBOV vaccine are now being tested in non-human primates.
Identifiants
pubmed: 37243081
pii: vaccines11050977
doi: 10.3390/vaccines11050977
pmc: PMC10223473
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : AI49170
Pays : United States
Organisme : CIHR
ID : 421693
Pays : Canada
Références
Cell Host Microbe. 2013 Feb 13;13(2):181-92
pubmed: 23414758
J Virol. 1998 Jun;72(6):4704-11
pubmed: 9573234
J Virol. 2013 Jan;87(1):2-15
pubmed: 23077317
Virology. 1994 Oct;204(1):266-78
pubmed: 8091657
J Virol. 2005 Apr;79(8):4991-9
pubmed: 15795284
J Virol. 1998 Apr;72(4):2855-64
pubmed: 9525605
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
JAMA. 2018 Mar 27;319(12):1261-1268
pubmed: 29584848
J Virol. 2001 Nov;75(21):10200-7
pubmed: 11581388
J Virol Methods. 2006 Jul;135(1):91-101
pubmed: 16569439
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Lancet Infect Dis. 2020 Apr;20(4):388-389
pubmed: 31952924
J Virol. 2004 May;78(9):4628-37
pubmed: 15078945
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Retrovirology. 2016 Nov 28;13(1):82
pubmed: 27894306
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8426-31
pubmed: 21536871
PLoS Pathog. 2020 Dec 28;16(12):e1009185
pubmed: 33370382
PLoS Pathog. 2014 Aug 07;10(8):e1004254
pubmed: 25101974
Cell. 2016 Jun 2;165(6):1467-1478
pubmed: 27238017
PLoS Pathog. 2021 Dec 16;17(12):e1010092
pubmed: 34914812
Science. 2016 Sep 2;353(6303):1045-1049
pubmed: 27540005
PLoS One. 2014 Sep 12;9(9):e106597
pubmed: 25215861
Science. 2015 Aug 14;349(6249):739-42
pubmed: 26249231
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Nucleic Acids Res. 1987 Feb 11;15(3):1281-95
pubmed: 3547335
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8388-92
pubmed: 7667300
J Infect Dis. 2012 Aug 1;206(3):431-41
pubmed: 22634875
J Virol. 2004 May;78(10):5458-65
pubmed: 15113924
J Virol. 2004 Jul;78(14):7582-9
pubmed: 15220433
Virology. 2000 Jul 5;272(2):417-28
pubmed: 10873786
Vaccine. 2020 Nov 25;38(50):7949-7955
pubmed: 33139138
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
J Virol. 2010 Feb;84(3):1439-52
pubmed: 19939925
Gene. 1991 Feb 15;98(2):177-83
pubmed: 2016060
J Virol. 2020 Nov 23;94(24):
pubmed: 33028714
AIDS. 2016 Jun 19;30(10):1543-51
pubmed: 27243773
Trends Microbiol. 2020 Aug;28(8):655-667
pubmed: 32418859
J Virol. 2013 Jan;87(2):923-34
pubmed: 23135713
BMC Bioinformatics. 2008 Jan 29;9:65
pubmed: 18230160
Curr Biol. 1996 Mar 1;6(3):315-24
pubmed: 8805248
Virology. 1998 Nov 25;251(2):244-52
pubmed: 9837788
J Virol. 2022 Jul 27;96(14):e0185121
pubmed: 35862673
J Virol. 1996 Apr;70(4):2318-23
pubmed: 8642658
NPJ Vaccines. 2022 Feb 28;7(1):27
pubmed: 35228534
Biotechniques. 2009 May;46(6):458-67
pubmed: 19480640
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a007351
pubmed: 23209178
J Virol. 2002 Dec;76(23):12325-34
pubmed: 12414973
J Virol. 2021 Jul 12;95(15):e0034221
pubmed: 33980600
Methods Mol Biol. 2016;1403:245-57
pubmed: 27076134
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
pubmed: 18063357
Virology. 2018 Jan 15;514:106-117
pubmed: 29175625
NPJ Vaccines. 2022 Nov 25;7(1):152
pubmed: 36433972
J Virol. 2022 Dec 21;96(24):e0108222
pubmed: 36448805
J Clin Microbiol. 2013 May;51(5):1517-27
pubmed: 23486708
Nature. 2006 Jun 15;441(7095):847-52
pubmed: 16728975
Viruses. 2010 May;2(5):1069-1105
pubmed: 21994672
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81
pubmed: 7753828
AIDS Res Ther. 2017 Sep 12;14(1):55
pubmed: 28893277
J Virol. 2000 Sep;74(18):8358-67
pubmed: 10954535
J Biol Chem. 1998 Jun 19;273(25):15773-8
pubmed: 9624176
AIDS Res Hum Retroviruses. 2014 Nov;30(11):1130-44
pubmed: 24597516